Ziv-Aflibercept
Fibrolamellar Carcinoma
National Cancer Institute (NCI)Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
26 Active assets in the Fibrolamellar Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Children's Oncology Group | Phase 3 | BB |
FLUOROURACILUM M.D. Anderson Cancer Center | Phase 3 | BB |
Nivolumab Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | B |
Sorafenib St. Jude Children's Research Hospital | Phase 3 | B |
ETOPOSIDE Children's Oncology Group | Phase 3 | B |
View all 37 →
Same molecule, other indications
Ziv-Aflibercept is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →